128,651 Shares in Pfizer Inc. (NYSE:PFE) Acquired by Guardian Partners Inc.

Guardian Partners Inc. purchased a new stake in Pfizer Inc. (NYSE:PFE - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 128,651 shares of the biopharmaceutical company's stock, valued at approximately $3,456,000.

Several other hedge funds have also recently bought and sold shares of the stock. PSI Advisors LLC lifted its holdings in shares of Pfizer by 1.4% in the 4th quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock worth $738,000 after acquiring an additional 385 shares during the last quarter. Waddell & Associates LLC lifted its stake in Pfizer by 1.6% in the third quarter. Waddell & Associates LLC now owns 24,978 shares of the biopharmaceutical company's stock worth $723,000 after purchasing an additional 388 shares during the last quarter. Patriot Financial Group Insurance Agency LLC boosted its position in Pfizer by 1.0% during the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company's stock valued at $1,027,000 after buying an additional 391 shares during the period. D Orazio & Associates Inc. grew its stake in shares of Pfizer by 5.5% during the fourth quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company's stock valued at $200,000 after buying an additional 391 shares during the last quarter. Finally, Lipe & Dalton lifted its stake in shares of Pfizer by 17.7% in the 4th quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock valued at $71,000 after acquiring an additional 400 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.06% of the stock is owned by company insiders.

Pfizer Stock Down 1.7 %

Shares of NYSE PFE traded down $0.44 during midday trading on Tuesday, hitting $25.71. The stock had a trading volume of 15,122,660 shares, compared to its average volume of 44,624,441. The business's 50 day moving average is $26.15 and its 200-day moving average is $27.02. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a market cap of $145.78 billion, a P/E ratio of 18.23, a PEG ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business's revenue for the quarter was up 24.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.10 earnings per share. As a group, analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on PFE. UBS Group lowered their price objective on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research note on Wednesday, January 8th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Truist Financial cut their price objective on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, December 18th. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, Citigroup cut their price target on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a report on Tuesday, January 28th. One analyst has rated the stock with a sell rating, seven have given a hold rating, six have issued a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, Pfizer currently has an average rating of "Moderate Buy" and a consensus target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.